Bajaj Healthcare Ltd (BAJAJHCARE) — shareholding pattern, promoter holding, financials and share price
About Bajaj Healthcare Ltd (BAJAJHCARE)
Bajaj Healthcare Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as BAJAJHCARE and on the BSE under scrip code 539872. Its ISIN is INE411U01027.
Incorporated in 1993, Bajaj Healthcare Ltd manufactures a wide range of Active Pharmaceutical Ingredients and Formulations [1]
Bajaj Healthcare Limited is a major pharmaceutical manufacturer specializing in APIs, finished dosage forms, and nutraceuticals. It operates 20 state-of-the-art manufacturing facilities and exports products to over 60 countries.
In FY 2025, Bajaj Healthcare achieved a total income of Rs 562.01 Cr, showcasing resilience amid challenging market conditions. The company maintains a net worth of Rs 486.39 Cr, illustrating a sound financial position.
Listed peers in Pharmaceuticals: Syncom Formulations (India) Ltd, Lincoln Pharmaceuticals Ltd, Accent Microcell Ltd, Fermenta Biotech Ltd, Themis Medicare Ltd, Wanbury Ltd.
Valuation & Returns
10 Jul 2026At ₹346.75 a share on 10 Jul 2026, Bajaj Healthcare Ltd (BAJAJHCARE) was valued at a price-to-earnings ratio of 54.77x against an industry P/E of 36.41x and a price-to-book of 2.5x on a book value of ₹138.48 per share as of Mar 2025. Solomo computes return on equity of 4.57% and return on capital employed of 7.42% from filed results. Earnings ratios use standalone results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 54.77x
- Industry P/E
- 36.41x
- P/B
- 2.5x
- EPS (TTM)
- ₹6.33
- Book value / share
- ₹138.48
- ROE
- 4.57%
- ROCE
- 7.42%
- ROA
- 2.56%
- Debt / equity
- 0.48x
- Dividend yield
- 0.29%
- EBITDA margin
- 11.97%
- 52-week range
- ₹272.45 – ₹552.55
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Bajaj Healthcare Ltd (BAJAJHCARE) reported revenue of ₹611 crore, net profit of ₹16 crore and earnings per share of ₹4.68. That compares with revenue of ₹543 crore and net profit of ₹40 crore in Mar 2025. Figures are standalone, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹153 crore and net profit ₹-23 crore (standalone).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 680 | 646 | 473 | 543 | 611 |
| Net profit (₹ cr) | 71 | 43 | -84 | 40 | 16 |
| EPS (₹) | 25.87 | 15.59 | -30.36 | 12.51 | 4.68 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 10.39% | 5.76% | -7.24% | 14.61% |
| Profit growth | 20.19% | 11.21% | -15.59% | 147.14% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 58.59% of Bajaj Healthcare Ltd (BAJAJHCARE) (up 0.3 pp QoQ), foreign institutional investors (FII) hold 2.19% and domestic institutional investors (DII) hold 1.92%. Market capitalisation was ₹1,167 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Sep 2016.
Largest disclosed public shareholders in Jun 2026: DEEPAK RAMANLAL JOSHI 2.32%, HDFC MUTUAL FUND - HDFC PHARMA AND HEALTHCARE FUND 1.69%, HUF 1.44%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 58.59% | - | 2.19% | 1.92% | 41.41% |
| Mar 2026 | 58.29% | - | 1.98% | 2.91% | 41.71% |
| Dec 2025 | 59.19% | - | 1.18% | 2.96% | 40.81% |
| Sep 2025 | 59.19% | - | 1.12% | 3% | 40.81% |
| Jun 2025 | 59.19% | - | 1.09% | 3.16% | 40.81% |
| Mar 2025 | 59.19% | - | 1.05% | 2.52% | 40.81% |
| Dec 2024 | 59.19% | - | 1.01% | 2.36% | 40.81% |
| Sep 2024 | 59.19% | - | 1.07% | 1.97% | 40.81% |